Johns Hopkins ABX Guide
Raltegravir
Raltegravir is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please log in or purchase a subscription.
Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Treatment of HIV-1 infection in combination with other ARV agents in ART-experienced patients with evidence of HIV replication despite ongoing ART.
- Treatment of HIV-1 infection in combination with other ARV agents in ART-naive patients.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- HIV-1 nonoccupational postexposure prophylaxis (nPEP): 400 mg tablet twice daily for 28 days in combination with other antiretrovirals. Therapy should be initiated within 72 hours.
- HIV-1 occupational postexposure prophylaxis (oPEP): 400 mg twice daily for 4 weeks with concomitant emtricitabine/tenofovir. Therapy should be initiated as soon as possible after occupational exposure.
- Substitution for other ARV agents due to drug toxicity or intolerance in pts on a suppressive regimen
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
FDA
- Treatment of HIV-1 infection in combination with other ARV agents in ART-experienced patients with evidence of HIV replication despite ongoing ART.
- Treatment of HIV-1 infection in combination with other ARV agents in ART-naive patients.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- HIV-1 nonoccupational postexposure prophylaxis (nPEP): 400 mg tablet twice daily for 28 days in combination with other antiretrovirals. Therapy should be initiated within 72 hours.
- HIV-1 occupational postexposure prophylaxis (oPEP): 400 mg twice daily for 4 weeks with concomitant emtricitabine/tenofovir. Therapy should be initiated as soon as possible after occupational exposure.
- Substitution for other ARV agents due to drug toxicity or intolerance in pts on a suppressive regimen
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: February 12, 2022
Citation
Kilcrease, Christin. "Raltegravir." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir.
Kilcrease C. Raltegravir. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir. Accessed March 29, 2023.
Kilcrease, C. (2022). Raltegravir. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir
Kilcrease C. Raltegravir [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2023 March 29]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Raltegravir
ID - 540471
A1 - Kilcrease,Christin,Pharm.D.
Y1 - 2022/02/12/
BT - Johns Hopkins ABX Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
